Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma
Part of paid clinical trials in Duarte, California.
- Sponsor
- City of Hope Medical Center
- Study ID
- NCT05363111
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Actinium Ac 225-DOTA-Daratumumab — BIOLOGICALGiven IV
- Daratumumab — BIOLOGICALGiven IV
- Indium In 111-DOTA-Daratumumab — BIOLOGICALGiven IV
Study Details
This phase I trial tests the safety, side effects, and best dose of actinium Ac 225-DOTA-daratumumab (225Ac-DOTA-daratumumab) in combination with daratumumab and indium In 111-DOTA-daratumumab (111In-DOTA-daratumumab) in treating patients with multiple myeloma that does not respond to treatment (refractory) or that has come back (recurrent). Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. 111In-DOTA-daratumumab and 225Ac-DOTA-daratumumab are forms of radioimmunotherapy in which a monoclonal antibody, daratumumab, has been linked to a radiotracer to allow for targeted delivery of the treatment to cancer cells. Giving all three together may kill more cancer cells.
Key Dates
- Start date
- Nov 22, 2022
- Status verified
- Oct 2025
- Primary completion
- Mar 23, 2027
- Completion
- Mar 23, 2027
Study Design
- Enrollment
- 15 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment (daratumumab, 225Ac/111In-DOTA-daratumumab)Patients receive daratumumab IV over 45 minutes. Two hours later, patients receive 111In-DOTA-daratumumab and 225Ac-DOTA-daratumumab IV over 20-30 minutes.
Primary Outcome Measure
Incidence of dose-limiting toxicities (DLTs) [ Time Frame: During the first 6 weeks post administration of study drug ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| City of Hope Medical Center | Duarte | California | 91010 | Scott R. Goldsmith (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Duarte, CA
Related Studies
- CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple MyelomaPHASE1 · Recruiting · City of Hope Medical Center · Duarte, California
- Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple MyelomaPHASE2 · Recruiting · City of Hope Medical Center · Duarte, California
- A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or LymphomaPHASE1 · Recruiting · Mayo Clinic · Scottsdale, Arizona
- Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple MyelomaRecruiting · Roswell Park Cancer Institute · Buffalo, New York